SCHEMBL6421670

SCHEMBL6421670

CCC(=O)c1ccccc1NC(C)=O

nearest known ligand 0.61

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 3/20 0.61
POLB P06746 2/20 0.61
CYP1A2 P05177 1/20 0.55
MAPK1 P28482 1/20 0.54
NPC1 O15118 5/20 0.54
RAB9A P51151 5/20 0.54
SMN1; SMN2 Q16637 4/20 0.54
ALDH1A1 P00352 3/20 0.53
HPGD P15428 1/20 0.53
TSHR P16473 2/20 0.53
MAPT P10636 1/20 0.51
KDM4E B2RXH2 2/20 0.50
LMNA P02545 2/20 0.50
BRD4 O60885 1/20 0.49
HTT P42858 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30040195 1.00 CYP2C19 (0.61) CYP2C19POLBCYP1A2MAPK1NPC1
SCHEMBL13623623 0.87 ALDH1A1 (0.64) POLBNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL6692404 0.86 MAPK1 (0.65) CYP2C19POLBCYP1A2MAPK1NPC1
SCHEMBL31570073 0.84 KMT2A (0.54) POLBMAPK1NPC1RAB9ASMN1; SMN2
SCHEMBL980175 0.84 CYP2C19 (0.59) CYP2C19POLBCYP1A2MAPK1NPC1
SCHEMBL8752477 0.84 CYP2C19 (0.59) CYP2C19POLBCYP1A2MAPK1NPC1
SCHEMBL11063870 0.83 POLB (0.46) CYP2C19POLBCYP1A2MAPK1NPC1
SCHEMBL3118542 0.82 CYP2C19 (0.57) CYP2C19POLBCYP1A2MAPK1NPC1
SCHEMBL8752502 0.82 KDM4E (0.60) CYP2C19POLBCYP1A2MAPK1NPC1
SCHEMBL605325 0.81 KDM4E (0.58) POLBNPC1RAB9ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-1316369-A None JP disclosed
CN-122080664-A Preparation method of organic pigment yellow without aromatic amine residue 2026-05-26 CN disclosed
CN-116947672-A Continuous preparation process of acetoacetanilide products 南通醋酸化工股份有限公司 2023-10-27 CN disclosed
US-20230027198-A1 INHIBITORS OF ENL/AF9 YEATS THE ROCKEFELLER UNIVERSITY 2023-01-26 US disclosed
US-20230027198-A1 INHIBITORS OF ENL/AF9 YEATS THE ROCKEFELLER UNIVERSITY 2023-01-26 US disclosed
CN-115427035-A ENL/AF9YEATS inhibitors 洛克菲勒大学 2022-12-02 CN disclosed
EP-4076440-A1 INHIBITORS OF ENL/AF9 YEATS The Rockefeller University (US) 2022-10-26 EP disclosed
WO-2021127166-A1 INHIBITORS OF ENL/AF9 YEATS THE ROCKEFELLER UNIVERSITY (US) 2021-06-24 WO disclosed
WO-2021127166-A1 INHIBITORS OF ENL/AF9 YEATS THE ROCKEFELLER UNIVERSITY (US) 2021-06-24 WO disclosed
EP-3080085-B1 FUSED BICYCLIC HETEROAROMATIC DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB BIOPHARMA SPRL (BE) 2019-08-14 EP disclosed
WO-2004087637-A1 PRODUCTION OF N-ALKYLAMIDE COMPOUNDS TAKASAGO INTERNATIONAL CORPORATION (JP) 2004-10-14 WO disclosed
US-6759429-B2 HAVING TRANSFORMING GROWTH FACTOR- BETA INHIBITORY ACTIVITY AND BEING USEFUL AS FIBROSIS INHIBITORS FOR ORGANS OR TISSUES SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2004-07-06 US disclosed
US-20030181496-A1 Pyrrole derivatives DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2003-09-25 US disclosed
EP-1310485-A1 PYRROLE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2003-05-14 EP disclosed
US-5075488-A Fungicides SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1991-12-24 US disclosed
EP-0128006-B1 A SOIL-DISEASE-CONTROLLING AGENT SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1991-09-18 EP disclosed
JP-H01316369-A 1-(4-AMINOPHENYL)-2-HEXAMETHYLENEIMINOPROPANONE LAB L LAFON SA 1989-12-21 JP disclosed
US-4709052-A FUNGICIDES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1987-11-24 US disclosed
EP-0128006-A2 A soil-disease-controlling agent SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1984-12-12 EP disclosed
US-4277420-A Ephedrine and pseudoephedrine precursors MONSANTO COMPANY (US) 1981-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230027198-A1 INHIBITORS OF ENL/AF9 YEATS MLLT3, YEATS2, MLLT1 CYP2C19 2083/4885POLB 4736/4885CYP1A2 2380/4885
US-20030181496-A1 Pyrrole derivatives NCOA1, PKD1, NR3C2 CYP2C19 1485/4885POLB 3063/4885CYP1A2 273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.